Effect of mazdutide on heart artery plaque in overweight individuals
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests a new medication called mazdutide to see if it can reduce plaque buildup in the heart arteries of people who are overweight and have a moderate narrowing. If you qualify, you may receive the drug or a placebo and will be monitored over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your BMI is 28 or higher, or your BMI is 24 or higher with at least one weight-related condition such as high cholesterol, fatty liver, high blood pressure, prediabetes, type 2 diabetes, or sleep apnea tied to obesity.
- You have a confirmed 30-70% narrowing in a coronary artery, as shown by a CT angiogram (CCTA) or coronary angiogram (CAG) within the last 3 months.
- You have not had severe or repeated low blood sugar episodes in the past 6 months.
- You have not had serious heart disease (like heart failure with very low pumping function), a recent stroke, or a mini-stroke within the past 6 months.
- You have not had pancreas problems (like pancreatitis) or gallbladder disease recently, and you do not have active cancer, HIV, or advanced liver disease.
- You are not taking weight-loss medications, certain diabetes drugs (GLP-1 receptor agonists), or participating in another clinical trial within 3 months.
- Your lab tests (like kidney and liver function) are within the acceptable range, and you have no allergy to contrast dye used in imaging tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding a medicine called Mazdutide after weight-loss surgery helps people with severe obesity achieve better results. It may be an option for those who qualify and are already planning to have sleeve gastrectomy.
This trial tests an investigational weight-loss medication (MDR-001) for people who are overweight or have obesity. Researchers want to see if this drug helps with weight loss and is safe when taken along with diet and exercise.
This trial tests whether combining lifestyle changes (diet and exercise) with a medication called mazdutide can help adults with obesity lose weight and keep it off. Mazdutide is an injectable medication that may help reduce appetite and support weight management over 2 years.
This study tests a once-weekly injection called mazdutide to help adults with prediabetes and higher weight lower their blood sugar and potentially lose weight. It is a double-blind, placebo-controlled trial, meaning some people get the real drug and some get a placebo (no active drug).
This study tests a new medication (mazdutide) to see if it can help people with type 2 diabetes achieve remission (normal blood sugar levels without needing diabetes medications). It is for adults with type 2 diabetes who are not well controlled on their current treatment (which can be diet and exercise alone, or metformin or an SGLT2 inhibitor). The study will last for a period of time, and participants will receive either the study drug or a placebo (inactive substance).
This trial is testing a new medication called Mazdutide to help treat PCOS in women with obesity. It aims to see if it improves PCOS symptoms and related health issues.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.